

Abhishek Tripathi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4884163/publications.pdf>

Version: 2024-02-01

38
papers

393
citations

933447

10
h-index

839539

18
g-index

38
all docs

38
docs citations

38
times ranked

586
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	4.1	70
2	Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. <i>Current Urology Reports</i> , 2018, 19, 109.	2.2	47
3	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	5.4	39
4	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.4	32
5	Androgen receptor in bladder cancer: A promising therapeutic target. <i>Asian Journal of Urology</i> , 2020, 7, 284-290.	1.2	25
6	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. , 2020, 8, e001467.		22
7	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. , 2020, 8, e000538.		19
8	Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 290-300.	3.9	19
9	The utility of next generation sequencing in advanced urothelial carcinoma. <i>European Urology Focus</i> , 2020, 6, 41-44.	3.1	18
10	Single Cell Mass Spectrometry Quantification of Anticancer Drugs: Proof of Concept in Cancer Patients. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 96-100.	4.9	18
11	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	2.5	18
12	PARP inhibitors in castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100199.	1.7	12
13	INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 428-428.	1.6	12
14	First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2501-2501.	1.6	7
15	Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5081-5081.	1.6	6
16	Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 98-98.	1.6	4
17	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	1.9	4
18	Perioperative Immunotherapy in Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2021, 4, 131-133.	5.4	3

#	ARTICLE	IF	CITATIONS
19	Association of prior local therapy and outcomes with programmedâ€œdeath ligandâ€œ1 inhibitors in advanced urothelial cancer. BJU International, 2022, 130, 592-603.	2.5	3
20	Patient-Reported Outcomes in Early Phase Clinical Trials: An Opportunity to Actively Promote Patient-Centered Care. Oncologist, 0, , .	3.7	3
21	PARP Inhibitors in Prostate Cancer: A Promise Delivered. European Urology Oncology, 2020, 3, 612-614.	5.4	2
22	SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.. Journal of Clinical Oncology, 2022, 40, TPS402-TPS402.	1.6	2
23	Outcomes with novel combinations in non-clear cell renal cell carcinoma(nccRCC): ORACLE study.. Journal of Clinical Oncology, 2021, 39, 4580-4580.	1.6	1
24	Nature versus Nurture: Investigating Racial Disparity in Advanced Prostate Cancer. Oncologist, 2021, 26, 904-905.	3.7	1
25	CD73 expression in primary and metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2018, 36, 643-643.	1.6	1
26	Association of time to second-line (2L) immune-checkpoint inhibitors (ICI) and outcomes with ICIs in patients (pts) with advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology, 2022, 40, 505-505.	1.6	1
27	Predictors of immunotherapeutic benefits in patients with advanced melanoma and other malignancies treated with immune checkpoint inhibitors utilizing ORIEN â€œreal-worldâ€œ data.. Journal of Clinical Oncology, 2022, 40, 2618-2618.	1.6	1
28	A deep learning approach utilizing clinical and molecular data for identifying prognostic biomarkers in patients treated with immune checkpoint inhibitors: An ORIEN pan-cancer study.. Journal of Clinical Oncology, 2022, 40, 2619-2619.	1.6	1
29	Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study.. Journal of Clinical Oncology, 2022, 40, 4545-4545.	1.6	1
30	A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.. Journal of Clinical Oncology, 2022, 40, TPS4618-TPS4618.	1.6	1
31	Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.. Journal of Clinical Oncology, 2021, 39, 406-406.	1.6	0
32	Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology, 2021, 39, 444-444.	1.6	0
33	Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.. Journal of Clinical Oncology, 2021, 39, e16526-e16526.	1.6	0
34	Editorial Comment. Journal of Urology, 2018, 200, 1214-1214.	0.4	0
35	Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).. Journal of Clinical Oncology, 2022, 40, 138-138.	1.6	0
36	DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.. Journal of Clinical Oncology, 2022, 40, 129-129.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Phase Ib study of avelumab and novel AXL inhibitor avb-S6-500 in patients with metastatic urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2022, 40, 4579-4579.	1.6	0
38	Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 5013-5013.	1.6	0